| Literature DB >> 36059814 |
Lucía Eguiguren-Jiménez1, Joshua Miles2, Jaime Ocampo3, Jeanette Mary Andrade1.
Abstract
Background: Ecuador has been experiencing an epidemiological transition due to its demographic and lifestyle changes, where non-communicable diseases are the leading cause of death, including chronic kidney disease (CKD). Quito, Ecuador's capital city, is one of the cities burdened by CKD, yet it is unknown the factors that contribute to the rising incidence of this disease. The purpose of this study was to estimate the prevalence of CKD among non-institutionalized adults in Quito between 2019 and 2021, and to examine its associations with various risk factors.Entities:
Keywords: blood glucose; blood pressure; chronic kidney disease; eGFR; prevalence
Year: 2022 PMID: 36059814 PMCID: PMC9437349 DOI: 10.3389/fmed.2022.908551
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Flow diagram of the selection process for the sample size.
Demographic characteristics.
|
|
|
|
|---|---|---|
| Sex ( | ||
| Females | 497 | 61.1 |
| Males | 316 | 38.9 |
| Zone ( | ||
| Urbana | 696 | 85.6 |
| Rural | 117 | 14.4 |
| Age ( | ||
| 18–44 | 334 | 41.1 |
| 45–64 | 287 | 35.3 |
| > 64 | 192 | 23.6 |
| CKD ( | ||
| eGFR <60 ml/min/1.73m2 | 58 | 7.2 |
| eGFR ≥ 60 ml/min/1.73m2 | 755 | 92.8 |
| Systolic blood pressure ( | ||
| <140 mmHg | 487 | 88.1 |
| ≥140 mmHg | 66 | 11.9 |
| Diastolic blood pressure ( | ||
| <90 mmHg | 530 | 95.8 |
| ≥90 mmHg | 23 | 4.2 |
| Blood Glucose ( | ||
| <126 mg/dl | 532 | 96.2 |
| ≥126 mg/dl | 21 | 3.8 |
Participants that met inclusion criteria for: age, sex, zone, and 2 serum creatinine measurements.
Participants that met inclusion criteria for: age, sex, zone, 2 serum creatinine, 2 blood pressure and 2 blood glucose measurements.
Prevalence of CKD by stage.
|
|
|
|
|---|---|---|
| Stage 1 (≥90) | 455 | 55.9 |
| Stage 2 (60–89.9) | 300 | 36.9 |
| Stage 3 (30–59.9) | 56 | 6.9 |
| Stage 4 (15–29.9) | 2 | 0.3 |
| Stage 5 (<15) | 0 | 0 |
Factors associated with eGFR (Model 1).
|
|
|
|
|
|
|---|---|---|---|---|
| (Intercept) | 145.51 (129.853, 161.161) | 7.97 | 18.26 | <0.01 |
| Systolic blood pressure | −0.426 (-0.584,−0.267) | 0.08 | −5.27 | <0.01 |
| Diastolic blood pressure | 0.082 (-0.171, 0.335) | 0.13 | 0.64 | 0.53 |
| Blood Glucose | −0.092 (-0.173,−0.012) | 0.04 | −2.25 | 0.03 |
Multiple linear regression (Model 1): R2 = 0.09, R2 adjusted = 0.09, p < 0.001;
p-value < 0.01.
Factors associated with eGFR (Model 2).
|
|
|
|
|
|
|---|---|---|---|---|
| (Intercept) | 156.41 (140.68, 172.14) | 8.01 | 19.53 | <0.01 |
| Systolic blood pressure | −0.43 (-0.58,−0.27) | 0.08 | −5.43 | <0.01 |
| Diastolic blood pressure | 0.16 (-0.09, 0.42) | 0.13 | 1.24 | 0.22 |
| Blood Glucose | −0.07 (-0.14, 0.01) | −0.04 | −1.61 | 0.11 |
| Sex | −3.87 (-7.30,−0.44) | 1.75 | −2.22 | 0.03 |
| Zone | −11.89 (-16.29,−7.49) | 2.24 | −5.30 | <0.01 |
Multiple linear regression (Model 2): R2 = 0.14, R2 adjusted = 0.14, p < 0.001;
p-value < 0.01;
p-value < 0.05.